Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Inovio: INO-4800 DNA Vaccine Against the Novel Coronavirus Has Promising News. Moderna Still Has the Front-Runner

Inovio DNA Vaccine Candidate INO-4800 for SARS-CoV-2 Inovio ( INO ) announced the publication of the preclinical study data for its novel coronavirus SARS-CoV-2 DNA vaccine INO-4800 which is demonstrating robust neutralizing antibody and T cell immune responses against COVID-19....

May 20, 2020

Sutro Biopharma: First Quarter Financial Results, Business Highlights and More

Sutro Biopharma Inc Sutro Biopharma ( STRO ) is a clinical-stage drug discovery, development and manufacturing company. Its expertise is in the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics. Sutro Biopharma reported its...

May 10, 2021

Cassava Sciences Awarded NIH Grant. See Also: Intellia Therapeutics Presentations at the 24th ASGCT Meeting

Cassava Sciences Awarded NIH Research Grant for Simufilam Cassava Sciences ( SAVA ) announced that it has been awarded a new $2.7 million research grant from the National Institutes of Health ( NIH ). The grant was awarded following a...

May 12, 2021

AstraZeneca and Amgen Product Tezepelumab Seems to Overcome the Resistance of Severe Asthma to Current Treatments

AstraZeneca and Amgen Announced Results for Tezepelumab for Severe Asthma Tezepelumab Reduced Exacerbations by 77% in Subgroup of Patients with Elevated Inflammatory Biomarkers in NAVIGATOR Tezepelumab Reduced Exacerbations Requiring Hospitalization by 85% AstraZeneca ( AZN ) and Amgen ( AMGN )...

May 14, 2021

More Vaccines from GlaxoSmithKline: One with Sanofi and Another with CureVac

Sanofi and GlaxoSmithKline COVID-19 Vaccine Sanofi ( SNY ) and GlaxoSmithKline ( GSK ) COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in the Phase 2 trial. Sanofi's and GlaxoSmithKline's adjuvanted recombinant COVID-19 vaccine candidate achieved...

May 17, 2021

Gilead Sciences: New Data Demonstrate Trodelvy Survival Benefit in Metastatic TNBC. See Also: Galapagos NV News

Gilead Sciences New Data from Trodelvy® Study Gilead Sciences ( GILD ) has recently announced new data from the Phase 3 ASCENT study evaluating Trodelvy® in patients with relapsed or refractory metastatic triple-negative breast cancer ( TNBC ) who received two...

September 17, 2021

Compugen: Predictive Computational Discovery Technology

Compugen IND Application for Triple Combination Study Cleared by the US FDA The U.S. Food and Drug Administration has cleared Compugen’s ( CGEN ) investigational new drug ( IND ) application for its Phase 1/2 study evaluating the triple combination...

June 1, 2020

Myovant Sciences Recent News is Good for Prostate Cancer Patients

Myovant Sciences Good News A lot of positive news is emanating from clinical trials conducted by development-stage biotechnology firms and revenue-generating firms. The good news in the small development-stage firms becomes more interesting when the trial results are from Phase...

June 3, 2020

Recursion Pharmaceuticals: A Step Forward Towards Improving C. Difficile Treatment

Recursion Pharmaceuticals Product REC-163964 Recursion Pharmaceuticals Inc ( RXRX ) announced the initiation of an investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential...

May 25, 2021

Aptevo Therapeutics Inc Product APVO436 Improves the Treatment of Resistant AML and MDS

Aptevo Therapeutics Inc in the News Aptevo Therapeutics Inc ( APVO ) has positive results from the Phase 1 dose-escalation trial evaluating its lead ADAPTIR candidate product APVO436 for the treatment of acute myeloid leukemia ( AML ) and myelodysplastic...

May 26, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024